StockTipsArenaBeta

BUY Piramal Pharma Limited — IDBI Capital

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))21 Sept 2026via IDBI Capital Research Calls Telegram

Entry₹211Stated
Target₹219
Total upside +3.79% (call closed)
Stop loss₹207-1.90% risk
Exit₹20725 Sept 2026, 10:45 am
Stop-loss hit-1.90%
Follow IDBI Capital for new calls(29% target hit, 425 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 2 active Swing calls on PPLPHARMASee 203 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 25 Sept 2026
2 supporting1 neutral1 opposing
Supports the BUY call (2)

Piramal Pharma earns ‘Leader’ ESG rating from independent assessor

NewsGoogle News·18 Sept · 6d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·26 Aug · 4w ago

Neutral / worth noting (1)

Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

NewsCnbc-Tv18·14 Sept · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility

NewsCnbc-Tv18·15 Sept · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from IDBI Capital

Every call and its outcome